Amivantamab

Amivantamab is a targeted therapy drug used to treat certain types of non-small cell lung cancer (NSCLC). It is a type of monoclonal antibody therapy, which works by binding to cancer cells and helping the body’s immune system recognize and attack them. Amivantamab is used in combination with other treatments, such as chemotherapy and radiation therapy, to slow the growth of cancer cells. It is also used to treat patients whose cancer has spread to other parts of the body and has not responded to other treatments.

Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat a specific type of non-small cell lung cancer (NSCLC) .

Here's a summary of Amivantamab:

• What it is: A bispecific antibody medication used to treat adults with locally advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy [1, 2].
• How it works: Amivantamab works by binding to two different proteins on cancer cells: the epidermal growth factor receptor (EGFR) and the mesenchymal-epithelial transition factor (MET). This binding helps to stop the growth and spread of cancer cells [1, 2].
• Brand name: Rybrevant [2].